Public Company Edition: NewAmsterdam grossed $328m in its SPAC merger, while Liminatus may raise up to $316m in a new SPAC deal. Also, Intellia and Iveric grossed $300m each in follow-on offerings, bluebird sold a PRV for $102m and MEI ends zandelisib development resulting in layoffs.

Amgen is enthusiastic about deals of all sizes, including a new Arrakis collaboration, and is interested in large transactions like its Otezla buy – but Bradway said right-priced opportunities are fewer and farther between. 

National Advertising Division sides with RxBar marketer in review of front-of-package list of ingredients and “No B.S.” statement challenged by Kind bars. NAD attorneys note food products commonly tout ingredients on labels without specifying relative prominence by weight, volume or other measures.

Warning letter and multiple form 483s fail to convince Custompax; Kellogg acquires RXBAR clean-label protein bars for $600m; NutraFuels used Blast Cap for products; and more news in brief.